FB825 for Eczema

Recruiting at 18 trial locations

Overseen By Jessica Ho

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Oneness Biotech Co., Ltd.

Must be taking: Emollients

Must not be taking: Systemic corticosteroids, JAK inhibitors

Disqualifiers: HIV, Hepatitis B/C, Drug abuse, others

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 2 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

Duration: 12 weeks

90 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment called FB825, an experimental monoclonal antibody, to determine its effectiveness for adults with moderate-to-severe eczema (atopic dermatitis) who haven't found success with other treatments like strong creams or ointments. Participants will receive either the experimental treatment or a placebo (a substance with no active medication) for comparison. The trial aims to assess FB825's effectiveness, how the body processes it, and its safety. Ideal candidates are adults who have had eczema for at least a year, covering at least 10% of their body, and have not found relief with typical treatments. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Will I have to stop taking my current medications?

The trial requires that you stop taking certain medications before starting, such as systemic corticosteroids, cyclosporine, and other immunosuppressants, at least 4 weeks prior. You can continue using stable doses of non-sedative antihistamines.

Is there any evidence suggesting that FB825 is likely to be safe for humans?

Research has shown that FB825 has been tested for safety in treating atopic dermatitis, a type of eczema. In an earlier study, participants handled FB825 well, with no major safety issues reported. This study was open-label, meaning everyone knew they were receiving FB825. Another study, more controlled and blinded (neither participants nor researchers knew who received the treatment), also examined the safety of FB825. This study aimed to ensure the treatment's safety while assessing how the body processes it. So far, results suggest that FB825 is generally safe for humans, with no major side effects noted in these trials. However, ongoing research will continue to provide more information on its safety. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising?

FB825 is unique because it targets the underlying immune mechanisms of eczema, potentially offering a different approach compared to standard treatments like topical corticosteroids and calcineurin inhibitors. Unlike these conventional treatments, which mainly focus on reducing inflammation and symptoms, FB825 works by modulating specific immune pathways that contribute to the condition. Researchers are excited about FB825 because it holds the promise of not only alleviating symptoms but also addressing the root cause of eczema with potentially longer-lasting effects.

What evidence suggests that FB825 might be an effective treatment for eczema?

Initial findings suggest that FB825, which participants in this trial may receive, might help treat atopic dermatitis, a common type of eczema. In an earlier study, patients using FB825 showed improvements in their skin condition. They reported needing less anti-inflammatory cream and experienced a better quality of life. These results are promising for those with moderate-to-severe eczema. The treatment targets specific parts of the immune system involved in eczema flare-ups. While more research is needed, these early results offer hope for its effectiveness. ^{1 2 3 6 7}

Who Is on the Research Team?

Chia-Yu Chu

Principal Investigator

National Taiwan University Hospital

Are You a Good Fit for This Trial?

Adults aged 18-65 with moderate-to-severe atopic dermatitis, who haven't responded well to topical treatments, can join this trial. They should have a history of the condition for at least 12 months and meet specific severity scores (EASI ≥16 and vIGA-AD ≥3). Participants must also have a significant area affected by eczema (>10% BSA) and experience intense itching.

Inclusion Criteria

My skin condition didn't improve after using strong skin creams for 4 weeks.

I weigh at least 40 Kg.

I have been diagnosed with severe skin eczema for over a year.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

4 weeks

Treatment

Participants receive 5 subcutaneous doses of FB825 or placebo over 12 weeks

12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 weeks

What Are the Treatments Tested in This Trial?

Interventions

• FB825

Trial Overview

The study is testing FB825, a new medication given as repeat subcutaneous injections, against a placebo. The goal is to see if FB825 is effective in reducing symptoms of atopic dermatitis. This process involves randomly assigning participants to either the treatment or placebo group without them knowing which one they're receiving.

How Is the Trial Designed?

Group I: FB825 Experimental Treatment 1 Intervention

Group II: Placebo Placebo Group 2 Interventions

FB825 is already approved in United States, China for the following indications:

Approved in United States as FB825 for:

• Atopic Dermatitis

Approved in China as FB825 for:

• Allergic Asthma

Who Is Running the Clinical Trial?

Oneness Biotech Co., Ltd.

Lead Sponsor

Trials

21

Recruited

1,200+

Published Research Related to This Trial

Monoclonal antibodies (mAbs) have led to improved treatment outcomes for various diseases, with 110 mAb preparations approved for use, including 46 for cancers and 66 for non-cancer disorders, highlighting their efficacy in targeting specific disease-associated biomarkers.

Despite their targeted approach, mAbs can cause serious hypersensitivity reactions and adverse events, including anaphylaxis and severe infusion reactions, due to cytokine release, indicating the need for careful monitoring during treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Immune- and Non-Immune-Mediated Adverse Effects of Monoclonal Antibody Therapy: A Survey of 110 Approved Antibodies. Baldo, BA.[2022]

Dupilumab shows a proportional increase in serum concentration with higher doses, indicating predictable pharmacokinetics, which is important for dosing strategies in treating conditions like atopic dermatitis.

The study found no need for dose adjustments based on ethnic origin or body weight, suggesting that dupilumab can be administered consistently across diverse populations without compromising safety or efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Dupilumab pharmacokinetics in Chinese healthy subjects and patients with atopic dermatitis: Results of two randomized, double-blind, placebo-controlled studies. Clot, PF., Kamal, M., Sun, J., et al.[2022]

Monoclonal antibodies are generally well tolerated and considered safe for treating allergic rhinitis, based on a systematic review of 12 studies involving over 2600 patients.

While adverse events were not statistically significant overall, urticaria was identified as a notable risk, indicating that specific hypersensitive reactions should be monitored closely during treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Adverse Events for Monoclonal Antibodies in Patients with Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Lin, Y., Wang, W., Zhu, Z., et al.[2023]

In a phase 2a study involving 113 adults with moderate to severe atopic dermatitis, tezepelumab showed a numerically greater efficacy compared to placebo, with 64.7% of patients achieving a ≥50% reduction in eczema severity (EASI50) at week 12.

The safety profile of tezepelumab was comparable to placebo, with similar rates of treatment-emergent adverse events, suggesting it is a safe option for patients when combined with topical corticosteroids.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial. Simpson, EL., Parnes, JR., She, D., et al.[2022]

Allergic diseases are becoming more common and are primarily driven by the activation of mast cells and the subsequent inflammatory response, which includes eosinophils.

Recent advancements in treatment include monoclonal antibodies like omalizumab, which specifically target IgE and other molecules involved in allergic responses, offering new hope for patients with severe asthma and atopic dermatitis where traditional glucocorticosteroids may not be effective.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17. Landolina, N., Levi-Schaffer, F.[2022]

In a phase III trial involving patients with moderate-to-severe atopic dermatitis, tralokinumab combined with topical corticosteroids showed significant efficacy, with 38.9% of patients achieving an Investigator's Global Assessment (IGA) score of 0/1 compared to 26.2% with placebo.

Tralokinumab was well tolerated, with a similar incidence of adverse events across treatment groups, indicating it is a safe option for patients needing systemic therapy for atopic dermatitis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Silverberg, JI., Toth, D., Bieber, T., et al.[2021]

In a study involving 11 allergic asthmatic subjects, the anti-IgE monoclonal antibody rhuMAb-E25 significantly increased the provocation concentration of allergens that could trigger asthma symptoms, indicating its potential efficacy in reducing asthma attacks.

rhuMAb-E25 was well tolerated with minimal side effects, leading to a substantial 89% reduction in serum-free IgE levels, which suggests it could be a promising new treatment for asthma management.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Boulet, LP., Chapman, KR., Côté, J., et al.[2015]

In a case series of nine patients with atopic dermatitis treated off-label with omalizumab, 50% showed a good or excellent response, indicating potential efficacy for severe cases of the condition.

A systematic review of 26 studies involving 174 patients found that 74.1% experienced some level of benefit from omalizumab, suggesting it is generally safe and well-tolerated, although further research is needed to confirm its effectiveness in larger trials.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Omalizumab for atopic dermatitis: case series and a systematic review of the literature. Holm, JG., Agner, T., Sand, C., et al.[2022]

REGN1908-1909, a combination of two monoclonal antibodies targeting the cat allergen Fel d 1, demonstrated linear pharmacokinetics and dose-proportional increases in serum concentrations, with a single 600 mg dose maintaining effective levels for 8-12 weeks.

The treatment showed no dose-limiting toxicities and was safe, with adverse events not being dose dependent, indicating a favorable safety profile for potential use in adults with cat allergies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

REGN1908-1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics. Kamal, MA., Dingman, R., Wang, CQ., et al.[2022]

In a phase 1 study involving 22 patients with moderate to severe atopic dermatitis, KHK4083 was found to have an acceptable safety profile, with no serious adverse events or discontinuations due to side effects.

Patients showed sustained improvement in atopic dermatitis symptoms, as indicated by significant reductions in Eczema Area and Severity Index (EASI) and thymus and activation-regulated chemokine (TARC) levels over the study period.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis. Nakagawa, H., Iizuka, H., Nemoto, O., et al.[2021]

In a phase II study involving 79 Japanese patients with severe atopic dermatitis, ustekinumab (45 mg and 90 mg) did not show significant improvement in the Eczema Area and Severity Index (EASI) score compared to placebo after 12 weeks.

Despite the lack of meaningful efficacy, ustekinumab was generally well tolerated, with common side effects including nasopharyngitis and worsened atopic dermatitis, which were more prevalent in the placebo group.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study. Saeki, H., Kabashima, K., Tokura, Y., et al.[2022]

Citations

1.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06397911

Study Details | NCT06397911 | Evaluate Efficacy and ...

This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in ...

2.

clinicaltrials.gov

clinicaltrials.gov/study/NCT03758716?spons=COVERAGE%5BFullMatch%5DEXPANSION%5BNone%5D(%22Fountain%20Biopharma%20Inc.%22)&viewType=Table&rank=2

NCT03758716 | An Open-Labeled Exploratory Study to ...

This is an open-labeled exploratory study to evaluate safety and efficacy of FB825 in adults with atopic dermatitis (AD). The study will be conduct at one ...

3.

trial.medpath.com

trial.medpath.com/clinical-trial/4649307a4432c62c/nct03758716-open-label-study-fb825-atopic-dermatitis

An Open-Labeled Exploratory Study to Evaluate Safety and ...

The purpose of this study is to evaluate the Safety and Efficacy of FB825 in Adults with Atopic Dermatitis.

4.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC8377708/

Atopic dermatitis: an expanding therapeutic pipeline for a ...

These encouraging efficacy data were confirmed by reduced use of TCSs as well as improved quality of life in the omalizumab-treated group.

5.

cdek.pharmacy.purdue.edu

cdek.pharmacy.purdue.edu/trial/NCT03758716/

Trial | NCT03758716

This is an open-labeled exploratory study to evaluate safety and efficacy of FB825 in adults with atopic dermatitis (AD). The study will be conduct at one ...

6.

synapse.patsnap.com

synapse.patsnap.com/drug/30d2f007562c44d8b8c4f9679e506bf2

FB-825 - Drug Targets, Indications, Patents

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Repeat Subcutaneous Doses of FB825 ...

7.

go.drugbank.com

go.drugbank.com/drugs/DB17598/clinical_trials?conditions=DBCOND0028414&phase=2&purpose=treatment&status=completed

FB-825 Completed Phase 2 Trials for Atopic Dermatitis ...

An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis. FB-825 (DB17598) ...